The role of allogeneic-cell transplantation in leukemia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.BMC cancer · 2019
   Trial
2. Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.Heliyon · 2023
   Review
3. Stem Cell Therapy and Innate Lymphoid Cells.Stem cells international · 2022
   Review
4. Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD.Blood advances · 2021
   Article
5. Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2020
   Article
6. HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group.JAMA oncology · 2018
   Article
7. Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease.The Journal of clinical investigation · 2017
   Article
8. The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation.Metabolomics : Official journal of the Metabolomic Society · 2016
   Article
9. Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT.Bone marrow transplantation · 2012
   Article
10. The EBMT activity survey: 1990-2010.Bone marrow transplantation · 2012
    Article
11. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.British journal of clinical pharmacology · 2012
    Article
12. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.JAMA · 2011
    Article
13. Stem cell transplantation for indolent lymphoma: a reappraisal.Blood reviews · 2011
    Review
14. The EBMT activity survey 2009: trends over the past 5 years.Bone marrow transplantation · 2011
    Article

Corrections and comments

• Comment on
  Reduced mortality after allogeneic hematopoietic-cell transplantation.2010

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as